Evidence analysisOctober 16, 2026Health & Science
Human medicines European public assessment report (EPAR): Idelvion, albutrepenonacog alfa, Date of authorisation: 11/05/2016, Revision: 14, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
Health & Science Evidence Dossier: Idelvion (albutrepenonacog alfa) for Haemophilia B
What is established
Idelvion is a medicinal product authorized for use in the European Union to prevent and treat bleeding episodes in patients with haemophilia B, an inherited disorder characterized by a deficiency of clotting Factor IX. The active ingredient, albutrepenonacog alfa, functions by replacing the missing clotting factor, thus facilitating blood coagulation and temporary control of bleeding.
Clinical studies involving adults, adolescents, and children have demonstrated that Idelvion is effective at preventing bleeding episodes, with a majority of patients experiencing no bleeding during prophylactic treatment. Additionally, approximately 93% of bleeding episodes treated with Idelvion resolved following a single injection.
The medicine is administered intravenously in the form of a reconstituted solution, with dosing individualized based on patient characteristics such as body weight, severity of Factor IX deficiency, bleeding severity, age, and health status. Treatment should be supervised by healthcare professionals experienced in haemophilia management.
Idelvion has been designated an orphan medicine due to the rarity of haemophilia B. It received marketing authorization in the European Union on 11 May 2016 after evaluation by the European Medicines Agency (EMA), which concluded its benefits outweigh its risks.
What the source claims
The source, a European Medicines Agency public assessment report updated as recently as October 2026, states that:
- Idelvion is effective in both prevention and treatment of bleeding in haemophilia B across age groups.
- The safety profile of Idelvion is comparable to other Factor IX replacement products.
- Rare but serious hypersensitivity reactions may occur, including local injection site reactions and systemic allergic symptoms.
- Development of inhibitors (antibodies) against Factor IX is a known risk, which may reduce treatment efficacy.
- There is a potential risk of thrombosis (blood clot formation) associated with Factor IX products.
- Idelvion is contraindicated in individuals allergic to the active substance or hamster proteins used in the manufacturing process.
- Measures including a risk management plan have been implemented to ensure safe use, with appropriate safety information made available in the product literature.
What may be missing from the usual framing
The EMA summary focuses on regulatory approval, clinical efficacy, typical adverse effects, and safety management for Idelvion. However, the report does not provide detailed information on:
- Long-term safety data beyond the clinical trial settings, including real-world effectiveness and rare adverse events that might appear post-marketing.
- Comparative data or direct head-to-head studies comparing Idelvion to other available Factor IX treatments on efficacy, safety, and cost-effectiveness.
- Patient quality of life assessments or psychosocial outcomes related to treatment with Idelvion.
- Information about access, pricing, or how regulatory and healthcare system factors may impact patient availability.
- Potential conflicts of interest or the extent to which the pharmaceutical company’s involvement influences assessment or dissemination.
Competing evidence or uncertainty
The EMA document does not cite contradictory evidence. However, uncertainties remain due to the inherent rarity of haemophilia B, limiting large-scale studies:
- The incidence of inhibitor development, while acknowledged, varies between different Factor IX therapies and patients; the source provides no comparative incidence rates or risk stratification details.
- The risk-benefit balance in specific subpopulations, such as very young children, elderly patients, or those with co-morbid conditions, may be insufficiently characterized.
- Long-term immunogenicity and the clinical implications of potential inhibitor formation remain areas of ongoing study.
- Thrombosis risk is noted but lacks quantified data or detailed guidance on risk minimization.
Outside sources may offer additional perspectives, but based on the single EMA assessment, comprehensive conclusions on broader or longer-term impacts are limited.
Why it matters
Haemophilia B is a rare but serious bleeding disorder requiring effective management to prevent morbidity and mortality from bleeding episodes. Replacement of deficient Factor IX is the cornerstone of treatment. Idelvion represents an important therapeutic option, designed for extended activity and convenient dosing schedules that can improve management adherence and quality of life.
Regulatory approval and post-market safety strategies help ensure patients receive treatments with demonstrated efficacy and monitored risks. However, understanding limitations and ongoing research needs is crucial for clinicians, patients, and policymakers to optimize care and resource allocation.
What to verify next
Further evidence and verification could focus on:
- Post-marketing surveillance data and real-world studies documenting safety and effectiveness over longer periods and across diverse patient groups.
- Comparative effectiveness research between Idelvion and other Factor IX products, including cost considerations and patient-reported outcomes.
- Data on the frequency, risk factors, and management of inhibitors and thrombosis associated with Idelvion.
- Independent systematic reviews and meta-analyses to contextualize the EMA findings within the broader scientific literature.
- Details about access barriers, including regulatory, economic, and healthcare system influences on patient availability.
Patients and healthcare providers should consult the original EMA source documents and product literature for comprehensive and up-to-date information, and discuss treatment options with qualified medical professionals.
Source & verification
Primary source: What's new · October 16, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

Burkina Faso Targets Critics in Exile
Accountability in Burkina Faso: Evidence Dossier on Judicial Repression of Critics Abroad What is established Since a military coup in September 2022, the ruling…

Human Rights Watch Mourns Death of Activist Nabeel Rajab
Human Rights Evidence Dossier: The Life and Legacy of Nabeel Rajab What is established Nabeel Rajab, a Bahraini human rights activist well-known for his…

Two more journalists murdered in Latin America, prompting press freedom concerns
Two More Journalists Murdered in Latin America: Press Freedom Under Threat In November 2026, Latin America witnessed a violent escalation against the press with…